Elvitegravir/cobicistat/emtricitabine/tenofovir
Combination of | |
---|---|
Elvitegravir | Integrase inhibitor |
Cobicistat | Cytochrome P450 inhibitor |
Emtricitabine | Reverse-transcriptase inhibitor |
Tenofovir disoproxil | Reverse-transcriptase inhibitor |
Clinical data | |
Trade names | Stribild |
AHFS/Drugs.com | Professional Drug Facts |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
ChemSpider |
|
KEGG |
Elvitegravir/cobicistat/emtricitabine/tenofovir, sold under the brand name Stribild, also known as the Quad pill, is a
The drug is manufactured by Gilead Sciences.
Serum creatinine (a marker of kidney function) may increase with use of Elvitegravir/cobicistat/emtricitabine/tenofovir. This is caused by cobicistat's inhibition of tubular secretion in the nephron. An increase of up to 0.3 mg/dL is expected; if serum creatinine level increases by 0.4 mg/dL or more, further evaluation for other causes of acute kidney injury is recommended.
Society and culture
Legal status
Elvitegravir/cobicistat/emtricitabine/tenofovir gained approval by the U.S. Food and Drug Administration (FDA) on August 27, 2012, for use in adults starting antiretroviral treatment for the first time as part of the fixed dose combination.[citation needed]
Economics
Gilead's stated wholesale price of Stribild is US$28,500 per patient, per year. Gilead maintains that its pricing is comparable to other HIV medications on the market. Elvitegravir/cobicistat/emtricitabine/tenofovir (Stribild) is priced at 39 percent higher than
References
- FDA. Retrieved 22 Oct 2023.
External links
- "Cobicistat mixture with elvitegravir, emtricitabine and tenofovir disoproxil fumarate". Drug Information Portal. U.S. National Library of Medicine.